Tempus ECG-Low EF vs PMcardio

Direct competitors — feature-level head-to-head below. Comparability 85/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Tempus AI
VS
by Powerful Medical

AI Verdict

Both Tempus ECG-Low EF and PMcardio are AI-powered tools designed for ECG analysis in cardiology and emergency medicine. While Tempus ECG-Low EF specifically focuses on detecting signs of low left ventricular ejection fraction (LVEF), PMcardio offers a broader interpretation, assessing over 50 cardiac conditions, including reduced LVEF. Clinicians might choose Tempus for a focused LVEF assessment or PMcardio for a more comprehensive ECG interpretation.

Choose Tempus ECG-Low EF if…

Choose Tempus ECG-Low EF if your primary need is an FDA-cleared AI software specifically designed for detecting signs associated with low left ventricular ejection fraction (LVEF ≤40%) in patients 40 years or older at risk of heart failure within a clinical diagnostic setting. This tool is ideal for integrating into existing healthcare facility workflows to aid clinicians in identifying patients who may require further evaluation for low LVEF.

View Tempus ECG-Low EF →

Choose PMcardio if…

Choose PMcardio if you require a versatile, CE-certified AI platform for rapid and comprehensive interpretation of over 50 cardiac conditions, including STEMI/OMI and reduced LVEF, with the flexibility of mobile and web deployment. This tool is well-suited for a broad range of healthcare professionals, including those in emergency medicine and primary care, who need expert-level ECG interpretations, AI explainability, and patient management recommendations at the point of care.

View PMcardio →

When choosing between Tempus ECG-Low EF and PMcardio, physicians should consider their primary diagnostic focus and workflow integration needs. Tempus ECG-Low EF is specifically designed for the detection of low left ventricular ejection fraction (LVEF ≤40%) in at-risk patients aged 40 and older, providing a clear binary output to aid in further evaluation. Its strength lies in this focused application, making it suitable for practices where identifying potential heart failure risk based on ECGs is a key concern.

In contrast, PMcardio offers a broader diagnostic capability, interpreting ECGs for over 50 cardiac conditions, including various arrhythmias, conduction disorders, and STEMI/OMI detection, in addition to reduced LVEF. The key practical difference lies in this scope: Tempus provides a targeted LVEF risk assessment, while PMcardio delivers a comprehensive, expert-level ECG interpretation across a wider range of conditions. Physicians primarily focused on screening for low LVEF and integrating a straightforward binary output into existing workflows may find Tempus ECG-Low EF more aligned with their needs. Conversely, those requiring a more extensive AI-powered ECG analysis for a multitude of cardiac conditions, with features like visual AI explainability and deployment across mobile and web platforms, would likely benefit more from PMcardio’s broader utility.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Tempus ECG-Low EF PMcardio
Pricing Contact vendor Freemium
Deployment Software, integrated into healthcare facility workflows Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems
BAA Available Yes AI-estimated Unknown
FDA Status Yes AI-estimated Pending AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

PMcardio

PMcardio offers deployment as a mobile app and web platform, making it highly accessible for individual clinicians at the point of care. It also features 'ECGxplainu2122' with visual AI explainability using heatmaps, which can enhance user understanding and trust. Tempus ECG-Low EF is described as software integrated into healthcare facility workflows and does not have a dedicated user interface, which suggests a less direct and potentially less intuitive user experience for individual clinicians.

Clinical Value

PMcardio

PMcardio detects over 50 cardiac conditions, including STEMI/OMI, rhythms, and reduced LVEF, and has been clinically validated in more than 25 studies. It also offers AI explainability and patient management recommendations based on ESC guidelines. Tempus ECG-Low EF focuses specifically on detecting signs associated with low LVEF and has received FDA clearance for this specific indication. While both offer value, PMcardio's broader diagnostic capabilities and extensive validation studies suggest greater overall clinical utility.

Pricing & Value

PMcardio

PMcardio offers a freemium model with a free plan for 5 ECG analyses per month and a transparent Pro Plan for unlimited use. Tempus ECG-Low EF requires contacting the vendor for pricing, indicating less transparency and potentially higher costs for individual users. PMcardio's clear pricing structure and free tier provide greater value and accessibility.

Enterprise Readiness

PMcardio

PMcardio for Organizations is a unified cardiac AI platform designed for enterprise-ready deployment, connecting to existing ECG systems, EHR/CVIS, and EMS systems with a single integration and security review. It offers multiple clinical suites and enterprise-level functionalities like central report management and workflow integration. Tempus ECG-Low EF is integrated into healthcare facility workflows and works with existing ECG platforms and EHRs, but PMcardio's comprehensive platform approach and explicit focus on system-wide cardiac care coordination demonstrate a higher degree of enterprise readiness.

Innovation

PMcardio

PMcardio demonstrates strong innovation with its detection of over 50 cardiac conditions, including advanced features like 'Queen of Heartsu2122' for STEMI/OMI detection and 'ECGxplainu2122' for visual AI explainability. It also offers patient management recommendations based on clinical guidelines. Tempus ECG-Low EF is an FDA-cleared AI for detecting low LVEF, which is innovative in its specific focus, but PMcardio's broader diagnostic scope and explainable AI features suggest a more comprehensive and forward-thinking approach to ECG interpretation.

Support & Docs

PMcardio

PMcardio provides a comprehensive 'Trust Center' with certificates, compliance documents, and system overviews, along with a help center, FAQ, and direct email support. Tempus offers general customer support via email and mentions a 'Document Library' and 'Policy Center' on its website. PMcardio's dedicated Trust Center and detailed resources suggest a more robust and transparent approach to support and documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Tempus ECG-Low EF PMcardio
Tool Name Tempus ECG-Low EF PMcardio
Company Tempus AI Powerful Medical
Regulatory Clearance FDA-cleared CE-certified
Primary Function Detects signs associated with low left ventricular ejection fraction (LVEF u226440%) Interprets ECGs to assess over 50 cardiac conditions
Target Patient Age (for LVEF detection) 40 years or older Not specified

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and PMcardio.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Tempus ECG-Low EF is designed to integrate with existing ECG platforms and EHRs to embed AI insights directly into clinical workflows. PMcardio offers enterprise integrations with EHR/CVIS and EMS systems, aiming for a unified platform that connects to existing ECG systems, angiographic systems, and communication tools.
Tempus ECG-Low EF achieved 85.8% sensitivity and 83.0% specificity in an independent validation cohort for detecting low LVEF. For PMcardio, studies have shown varying accuracy depending on the condition; for major ECG abnormalities, it demonstrated 86% sensitivity and 92% specificity, and for AF, 97% sensitivity and 99% specificity. PMcardio's Queen of Hearts platform for STEMI detection has shown 92% sensitivity and 81% specificity, outperforming standard processes.
PMcardio aims to standardize diagnostic skills and offers an 'ECGxplain' feature with visual AI explainability (heatmaps) to enhance transparency and build clinician confidence, which can be particularly beneficial for early-career clinicians and for reviewing challenging cases. Tempus ECG-Low EF provides a binary output, and results should be interpreted in conjunction with other diagnostic information.
PMcardio for Organizations is built for system-wide rollout, offering one integration, one contract, and one security review, and can scale across campuses and care settings without custom builds. Health systems using PMcardio's Acute Care Suite have reported reductions in door-to-balloon times by up to 48 minutes and 6 hours faster treatment for STEMI equivalents.
PMcardio has several case studies and testimonials, including instances where it helped paramedics with faster and more accurate STEMI detection and assisted physicians in managing acute heart failure patients. PMcardio is trusted by over 100,000 clinicians and 50+ health systems worldwide. Tempus AI highlights that its ECG-AI solutions are designed to support clinicians in identifying patients at risk for cardiovascular conditions earlier in their care journey.
Tempus ECG-Low EF is specifically for detecting signs associated with low LVEF (u226440%) in patients 40 years or older at risk of heart failure, analyzing resting 12-lead ECGs. It is not a stand-alone diagnostic tool, should not be used for patient monitoring, or on ECGs with paced rhythms. PMcardio offers broader detection of over 50 cardiac conditions, including STEMI/OMI, rhythms, reduced LVEF, and conduction disorders, and is intended for use by various healthcare professionals at the point of care. PMcardio's AI models are trained on over 2.5 million ECGs.

Backers

Who funded each tool's parent company.

Tempus ECG-Low EF

PMcardio

AI Tool Finder
AI-powered search. Results may not be comprehensive.